1. Introduction
===============

The deep sea is an extreme environment which is still marginally investigated and harbors a great variety of bacteria that have, so far, not been cultivated. Bacteria which live in the deep sea need to adapt to the specific environmental characteristics such as high hydrostatic pressure, low temperature and only occasional nutrient supply. These constraints quite likely determine the phylogenetic diversity of the deep-sea bacterial communities and also affect the secondary metabolite production of these bacteria. Therefore, deep-sea bacteria are considered as a promising source for the discovery of new natural products. Marine members of *Actinobacteria* are highly potent producers of interesting compounds \[[@b1-marinedrugs-09-00098]--[@b5-marinedrugs-09-00098]\] as was already shown for their terrestrial counterparts \[[@b6-marinedrugs-09-00098]\]. Only recently, two strains of *Streptomyces* sp. from the Atlantic ocean deep-sea sediment were shown to produce the two new natural products caboxamycin and albidopyrone \[[@b7-marinedrugs-09-00098],[@b8-marinedrugs-09-00098]\].

With special focus on the discovery of new natural products, we selectively isolated *Actinobacteria* from the deep-sea sediment of the Eastern Mediterranean Sea (the so-called Levantine Sea). This environment is characterized by a relatively high bottom temperature of 13--14 °C, salinity values of approximately 38--39‰, high hydrostatic pressure (440 bar at the sampling site) and an extreme depletion of nutrients \[[@b9-marinedrugs-09-00098]\]. Among the isolated bacteria, strain M71-A77 produced two new macrolides named levantilides A (**1**) and B (**2**), which will be described in this paper.

2. Results and Discussion
=========================

Strain M71-A77 was isolated from the Eastern Mediterranean deep-sea sediment (4400 m) and revealed 99.3% 16S rRNA gene sequence similarity to *Micromonospora auratinigra* DSM 44815^T^ (AB159779). Analyses of the culture extract of this strain (incubated in liquid soja-peptone medium) by HPLC-DAD-MS led to the detection of two unknown 20-membered macrolides, levantilide A (**1**) and B (**2**), with detected masses of *m/z* 508 and *m/z* 506, respectively. Subsequent cultivation of the strain in larger scale (10 L) led to the isolation of the levantilides as colorless solids.
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Levantilide A (**1**) had a measured molecular mass of *m/z* 531.3676 \[M + Na\]^+^ (calculated for C~30~H~52~NaO~6~ 531.3656), which yielded the molecular formula C~30~H~52~O~6~ and implied five degrees of unsaturation. The structure elucidation of the compound was mainly based on one- and twodimensional NMR spectra of **1**. The respective ^13^C NMR spectrum displayed 30 distinct signals ([Table 1](#t1-marinedrugs-09-00098){ref-type="table"}) which were consistent with the deduced molecular formula. The carbon resonances gave evidence of one carbonyl carbon (δ~C~ 166.1 ppm), one olefinic quaternary carbon (δ~C~ 132.8 ppm), five olefinic methine carbons (δ~C~ 120.4 ppm to 143.8 ppm), five methine carbons adjacent to oxygen atoms (δ~C~ 67.2 ppm to 77.4 ppm), four further methine carbons (δ~C~ 29.4 ppm to 41.0 ppm), eight methylene groups (δ~C~ 22.0 ppm to 40.9 ppm) and six methyl groups (δ~C~ 10.1 ppm to 21.5 ppm). The HSQC spectrum allowed all carbon resonances to be unambiguously assigned to the resonances of their directly attached protons. The final planar structure of the molecule was deduced from COSY and HMBC spectra ([Figure 1](#f1-marinedrugs-09-00098){ref-type="fig"}). With a shift of 166.1 ppm, the carbonyl carbon C-1 was very likely to belong to a conjugated ester function. HMBC correlations from H-3 (δ~H~ 7.06) and H-2 (δ~H~ 5.78) identified the adjacent methine groups. H-2 to H-5 (δ~H~ 6.08) were all olefinic protons which coupled to each other. H-5 showed HMBC correlations to C-3 (δ~C~ 143.8) as well as to C-6 (δ~C~ 39.6), a methylene carbon, and C-7 (δ~C~ 67.2), a hydroxylated methine. H-7 (δ~H~ 3.98) showed COSY correlations to H-6 as well as to the methylene group CH~2~-8 (δ~C~ 33.4, δ~H~ 1.51; 1.16). Next to CH~2~-8, there followed four methine groups, CH-9 to CH-12, each of them substituted with either a hydroxy group, CH-9 (δ~C~ 67.4, δ~H~ 3.92) and CH-11 (δ~C~ 75.3; δ~H~ 2.98), or a methyl group, CH-10 (δ~C~ 41.0; δ~H~ 1.68) and CH-12 (δ~C~ 32.1 and δ~H~ 1.24), which could be unequivocally proven by their shifts, COSY and HMBC correlations. Not only did the COSY correlations of the methyl groups CH~3~-29 (δ~C~ 17.7 and δ~H~ 0.58) and CH~3~-30 (δ~C~ 11.1 and δ~H~ 0.86) connect them to the methine groups CH-12 and CH-10, but their HMBC correlations also gave further evidence of the positions of the neighboring carbons and secured the sequence from CH-9 to CH-12. Furthermore, a methylene group CH~2~-13 (δ~C~ 40.1, δ~H~ 1.87 and 1.51) was shown to connect the methine groups CH-9 to CH-12 to the quaternary olefinic carbon C-14 (δ~C~ 132.8). Therefore, the last double bond evidently was located between C-14 and C-15 (δ~C~ 132.7). The corresponding proton H-15 (δ~H~ 4.76) showed long range couplings to C-17 (δ~C~ 40.9), C-13, C-16 (δ~C~ 29.4), C-27 (δ~C~ 21.5) and C-28 (δ~C~ 17.0) and coupled to H-16 and H~2~-13. CH~2~-17 (δ~H~ 1.34 and 1.05) formed the junction between the methyl-bearing methines CH-16 and CH-18 as indicated by HMBC correlations from H-17 to C-18 (δ~C~ 33.4), C-26 (δ~C~ 17.5) and C-27. The substructure was further supported by COSY correlations of the same proton signal (H-17) to the resonances of H-16 (δ~H~ 2.59) and H-18 (δ~H~ 1.75). CH-19 (δ~C~ 77.4; δ~H~ 4.71), the methine adjacent to CH-18, closed the macrolide ring as proven by its HMBC correlation to C-1 and connected it to the side chain of the molecule by correlations to the methylene groups CH~2~-20 (δ~C~ 27.9; δ~H~ 1.52 and 1.47) and CH~2~-21 (δ~C~ 22.0; δ~H~ 1.30). After the carbonyl group and the three double bonds, one degree of unsaturation still had to be accounted for, which was accomplished by the closure of the ring. Analysis of the NMR spectra gave evidence of a 3-hydroxy-hexyl-side chain. All double bonds, Δ^2,3^, Δ^4,5^ and Δ^14,15^, were determined to be *E*-configured. For the double bonds Δ^2,3^ and Δ^4,5^, the configuration was deduced from the ^3^*J* coupling constants of approximately 15 Hz. Δ^14,15^ is a trisubstituted double bond, therefore the NOESY spectrum had to be consulted. As H-15 showed NOESY-correlations to H~2~-13, but not to H~3~-28, this double bond, too, had to be *E*-configured. Thus, the planar structure of levantilide A could be unambiguously delineated from the spectroscopic data.

The derivative, levantilide B (**2**), showed a mass difference of 2 amu in the HPLC-DAD-MS measurement, which indicated one additional double bond, which for example can be observed, when a hydroxy-group is replaced by a carbonyl function, as it was the case here. Already in the ^1^H NMR spectrum it was obvious that all signals belonging to protons of the macrolide ring were identical in both molecules (see [Table 2](#t2-marinedrugs-09-00098){ref-type="table"}). However, significant differences could be observed for the signals of the side chain. Analysis of the data showed that the methine group CH-23 was no longer present in levantilide B. Instead of it, an additional signal of a carbonyl carbon appeared, its shift of 210.5 ppm proving it to be a ketone. As a consequence of the presence of a carbonyl group instead of a methine in position 23, the signal of H~2~-24 was no longer a multiplet, but appeared as a quartet as it only coupled with the methyl group CH~3~-25. Thus, the planar structure of **2** was established as depicted.

The levantilides are macrolides with a 20-membered lactone ring. From a biosynthetic point of view macrolides are typical type I PKS products with very well studied biosynthetic pathways. From the structures of the levantilides, a very simple assembly of a propionate starter unit, five further propionate building blocks and altogether six acetate building blocks can be deduced.

Cytotoxicity tests of **1** revealed antiproliferative activities against gastric tumor cells GXF 251L (IC~50~ = 40.9 μM), lung tumor cells LXFL 529L (IC~50~ = 39.4 μM), mammary tumor cells MAXF 401NL (IC~50~ = 28.3 μM), melanoma tumor cells MEXF 462NL (IC~50~ = 48.6 μM), pancreas tumor cells PAXF 1657L (IC~50~ = 20.7 μM) and renal tumor cells RXF 486L (IC~50~ = 52.4 μM). Antimicrobial activity against the bacteria and fungi in the test panel were not observed for compounds **1** and **2**.

Members of the *Actinomycetes* are well known to produce macrolide antibiotics \[[@b10-marinedrugs-09-00098]\]. Micromonospolides, mycinamicins, megalomicin, rosamicin and juvenimicins are e.g., macrolide antibiotics produced by members of the genus *Micromonospora*, but they all differ in the size of the macrolide ring from the levantilides \[[@b11-marinedrugs-09-00098]--[@b15-marinedrugs-09-00098]\]. The levantilides are 20-membered macrolides without an attached sugar and are, for example, related to the cytotoxic macrolides amphidinolide A and U \[[@b16-marinedrugs-09-00098],[@b17-marinedrugs-09-00098]\] as well as to iriomoteolide 1a, b and c \[[@b18-marinedrugs-09-00098],[@b19-marinedrugs-09-00098]\]. These compounds are also 20-membered marcolides which exhibit cytotoxic activity against several human tumor cell lines \[[@b20-marinedrugs-09-00098]--[@b22-marinedrugs-09-00098]\] and are produced by the marine symbiontic dinoflagellate *Amphidinium sp*. Iriomotolide 1a, 1b and 1c show remarkable cytotoxicity against B lymphocyte cells DG75 (IC~50~ = 0.0039 μM, 1.7 μM and 0.0038 μM) while amphidinolide A and U possess cytotoxic activities against murein lymphoma cells L1210 (IC~50~ = 3.7 μM and 10.7 μM) and against human epideromoid carcinoma cells (IC~50~ = 10.7 μM and 35.08 μM).

According to Skropeta (2008), polyketide metabolites have been reported from all water depths, but interestingly only 8% of the marine natural products known so far are produced by organisms obtained at depth greater than 1000 m \[[@b23-marinedrugs-09-00098]\]. As a matter of course, this might be due to the fact that the deep sea is hardly accessible. In the present study, it was shown by cultivation of strain M71-A77 with habitat sea water (38.6‰) that levantilides are also produced under the high salinity conditions occurring *in situ* in the Mediterranean Sea. Though strains of *Micromonospora spp.* were frequently isolated from deep sea habitats \[[@b24-marinedrugs-09-00098]--[@b26-marinedrugs-09-00098]\], to the best of our knowledge the levantilides are the first natural products described from a *Micromonospora* sp. strain isolated from the deep sea.

3. Experimental Section
=======================

3.1. Isolation and identification of strain M71-A77
---------------------------------------------------

Strain M71-A77 has been isolated from a sediment core (1.5--5 cm sediment horizon) from 4400 m depth during a research cruise with RV Meteor M71/2 in the Eastern Mediterranean Sea, the so-called Levantine Sea \[34° 25.48 N, 26° 05.39 E\]. One gram of the sediment sample was transferred to a sterile petri dish and dried for 2 months at 20 °C prior to incubation for 1 h at 120 °C dry heat. Sediment was then re-suspended in demineralized water and inoculated on agar plates of XJ4-medium containing of 1 L of demineralized water 18 g agar, 0.1 g histidine, 1 g raffinose, 0.5 g sodium hydrogen phosphate, 1.7 g potassium chloride, 0.05 g magnesium sulfate, 0.01 g iron sulfate, 0.02 g calcium carbonate, 0.5 mg thiamine hydrogen chloride, 0.5 mg riboflavine, 0.5 mg niacine, 0.5 mg piridoxin, 0.5 mg calcium pantothenate, 0.5 mg inositol, 0.5 mg para aminobenzoic acid and 0.25 mg biotin. After 2 months of incubation at 28 °C, strain M71-A77 was isolated by transferring to fresh XJ4-medium. The strain was classified by 16S rRNA gene sequence analysis according to Gärtner *et al.* \[[@b27-marinedrugs-09-00098]\]. The 16S rRNA gene sequence was deposited in the EMBL Nucleotide Sequence Database and was assigned the accession no. FR714833.

3.2. Chemical analysis
----------------------

### General experimental procedures

The optical rotation was measured on a Perkin Elmer model 241 polarimeter. UV-spectra were obtained on a NanoVue (GE Healthcare). NMR spectra were recorded on a Bruker DRX500 spectrometer (500 and 125 MHz for ^1^H and ^13^C NMR, respectively), using the signals of the residual solvent protons and the solvent carbons as internal references (*δ*~H~ 2.04 and *δ*~C~ 28.9 ppm for acetone-*d*~6~; *δ*~H~ 2.50 and *δ*~C~ 39.51 ppm for DMSO-*d*~6~). High-resolution mass spectra were acquired on a benchtop time-of-flight spectrometer (MicrOTOF, Bruker Daltonics) with positive electrospray ionization. Analytical reversed phase HPLC-UV/MS experiments were performed using a C~18~ column (Phenomenex Onyx Monolithic C18, 100 × 3.00 mm) applying an H~2~O (A)/MeCN (B) gradient with 0.1% HCOOH added to both solvents (gradient: 0 min 5% B, 4 min 60% B, 6 min 100% B; flow 2 mL/min) on a VWR Hitachi Elite LaChrom system coupled to an ESI-ion trap detector (Esquire 4000, Bruker Daltonics). Preparative HPLC was carried out using a Phenomenex Gemini C18 110A AXIA, 100 × 50.00 mm column.

### Isolation of levantilides A and B

10 L of liquid starch-peptone medium (1L demineralized water 10 g starch, 5 g soja peptone, 15 g Tropic Marin® sea salt and 1 g calcium carbonate) were used for cultivation of strain M71-A77. After 8 days of incubation (28 °C, 125 rpm), the culture supernatant was separated from the cells by centrifugation at 10,000 rpm for 10 min (Beckman J2-MC). Cell pellets were suspended in methanol and homogenized three times with an Ultra Turax T25 basic (IKA-Werke GmbH & Co., Staufen, Germany) at 17.500 U/min for 1 min. After additional centrifugation, the methanol extract was decanted and dried. The culture broth supernatant was extracted with ethylacetate (1:1). The dried extracts were dissolved in methanol and analyzed by HPLC-UV/MS. Levantilides A and B were detected at 4.2 and 4.5 min with a maximum UV-absorption at 260 nm. For structure analysis, **1** and **2** were separated by reversed phase HPLC. For that purpose, HCOOH (0.1%) was added to the solvents H~2~O (A) and MeCN (B) and a gradient from 10% B over 60% B (reached after 17 min) to 100% B was applied (flow 15 mL/min). Levantilides A and B were detected at 16.6 and 17.8 min. Thus, 7 mg of **1** and 3 mg of **2** were obtained.

**Levantilide A (1):** colorless, amorphous solid; \[α\]^20^ [d]{.smallcaps} −72.4 (*c* 0.145, MeOH); UV (MeOH) λ~max~ (log ɛ) 262 (4.61); for 1D and 2D NMR data see [Table 1](#t1-marinedrugs-09-00098){ref-type="table"} and SI; HRESIMS *m/z* 531.3676 \[M + Na\]^+^ (C~30~H~52~NaO~6~, 531.3656).

**Levantilide B (2):** colorless, amorphous solid; \[α\]^20^ [d]{.smallcaps} −97.5 (*c* 0.04, MeOH); UV (MeOH) λ~max~ 261 (log ɛ) (4.48); ^1^H NMR (acetone-*d*~6~, 500 MHz) δ 7.15 (1H, dd, *J* = 15.1, 11.0, H-3), 6.36 (1H, dd, *J* = 15.1, 11.0, H-4), 6.11 (1H, ddd, *J* = 15.1, 9.8, 4.4, H-5), 5.83 (1H, d, *J* = 15.1, H-2), 4.87 (1H, d, *J* = 8.0, H-15), 4.81 (1H, dt, *J* = 10.2, 2.5, H-19), 4.17 (1H, dt, *J* = 11.9, 3.1, H-9), 4.10 (1H, m, H-7), 3.18 (1H, m, H-11) 2.69 (1H, m, H-16), 2.66 (1H, m, H-6a), 2.46 (1H, m, H-6b), 2.45 (2H, m, H~2~-22), 2.42 (2H, q, *J* = 7.5, H~2~-24), 1.99 (1H, m, H-13a), 1.87 (1H, m, H-18), 1.86 (1H, m, H-10), 1.72 (1H, ddd, *J* = 15.0, 11.2, 3.3, H-8a), 1.69 (1H, dd, *J* = 13.1, 10.9, H-13b), 1.63 (3H, s, H~3~-28), 1.62 (1H, m, H-21a), 1.57 (1H, m, H-20a), 1.50 (1H, m, H-20b), 1.47 (1H, m, H-21b), 1.43 (1H, m, H-17a), 1.41 (1H, m, H-12), 1.34 (1H, ddd, J = 15.0, 5.4, 3.0, H-8b), 1.11 (1H, ddd, *J* = 14.6, 9.0, 5.1, H-17b), 0.98 (3H, d, *J*=7.0, H~3~-30), 0.96 (3H, t, *J* = 7.5, H~3~-25), 0.91 (3H, d, *J* = 7.5, H~3~-26), 0.87 (3H, d, *J* = 7.0, H~3~-27), 0.71 (3H, d, *J* = 7.0, H~3~-29); for ^13^C NMR data see [Table 2](#t2-marinedrugs-09-00098){ref-type="table"}; HRESIMS *m/z* 529.3509 \[M + Na\]^+^ (C~30~H~50~NaO~6~, 529.3500).

3.3. Production of levantilide A (1) and B (2) at in situ salinity
------------------------------------------------------------------

Strain M71-A77 was tested for the production of secondary metabolites at habitat salinity (38.6 ‰). For that purpose, Tropical Marine® salt and aqua dest. were replaced by Mediterranean Sea water obtained from the sampling site. After 8 days of cultivation at 28 °C, the culture broth was extracted with ethylacetate and analyzed by analytical HPLC-UV/MS as described above.

3.4. Antimicrobial tests
------------------------

Antimicrobial activity of compound **1** and **2** (100 μM) was tested against the Gram-positive bacteria *Bacillus subtilis* (DSM 347)*, Staphylococcus lentus* (DSM 6672)*,* the Gram-negative bacteria *Xanthomonas campestris* (DSM 2405)*, Escherichia coli* (DSM 498)*, Erwinia amylovora* (DSM 50901)*, Pseudomonas fluorescens* (NCIMB 10586)*, Pseudomonas syringae* (DSM 50252)*, Ralstonia solanacearum* (DSM 9544), the yeast *Candida glabrata* (DSM 6425) and the fungus *Septoria tritici* as described by Lang *et al.* in 2007 \[[@b28-marinedrugs-09-00098]\]. The results were compared to a positive (100 μM chloramphenicol for bacteria and 100 μM cycloheximide for *C. glabrata* and *S. tritici*) and a negative (no compound) control on the same plate.

3.5. Cytotoxic tests
--------------------

The *in vitro* antiproliferative activities of compound **1** against the gastric cancer cell line GXF 251L, lung cancer cell line LXFL 529L, melanoma cancer cell line MEXF 462NL, mammary cancer cell line MAXF 401NL, renal cancer cell line RXF 486L and pancreatic cancer cell line PAXF 1657L were determined by Oncotest GmbH (Freiburg, Germany) using a modified propidium iodide monolayer assay \[[@b29-marinedrugs-09-00098]\]. Compound **2** was not tested by Oncotest GmbH, for there was not enough left of the compound.
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###### 

NMR spectroscopic data (500 MHz, DMSO-*d*~6~) of levantilide A (**1**).

  levantilide A (1)                                                                                                                              
  ------------------- ------------- ------------------------------------------------------------- ----------------- ---------------------------- ---------------
  1                   166.1, C                                                                                                                   
  2                   120.4, CH     5.78, d (15.5)                                                3                 1, 3, 4, 5                   3, 4
  3                   143.8, CH     7.06, dd (11.2, 15.5)                                         2, 4              1, 2, 4, 5                   2, 4, 5
  4                   130.6, CH     6.29, dd (11.2, 15.2)                                         3, 5              2, 3, 6                      2, 3, 5, 6b
  5                   139.8, CH     6.08, ddd (4.4, 10, 15.2)                                     4, 6              3, 6, 7                      3, 4, 6a, 7
  6a                  39.6, CH~2~   2.57, m                                                       5, 6b, 7          4, 5, 7, 8                   5
  6b                                2.33, dt (14.4, 9.9)                                          5, 6a, 7          4, 5, 7, 8                   4
  7                   67.2, CH      3.98, m                                                       6, 7-OH, 8                                     8b, 5
  7-OH                              4.81, br. d (3.8)                                             7                 7, 8                         
  8a                  33.4, CH~2~   1.51[a](#tfn1-marinedrugs-09-00098){ref-type="table-fn"}, m   7, 8b, 9          6, 7, 9                      8b
  8b                                1.16, ddd (14.6, 5.6, 2.3)                                    7, 8a, 9          6, 7, 9                      7, 8a, 11
  9                   67.4, CH      3.92, br. d (11.2)                                            8, 9-OH, 10       30                           12
  9-OH                              4.63, br. s                                                   9                 8, 9, 10                     
  10                  41.0, CH      1.68, m                                                       9, 11, 30                                      
  11                  75.3, CH      2.98 br. ddd (8.9, 6.0, 1.8)                                  10, 11-OH, 12     9, 10, 12, 13, 29, 30        8b, 29
  11-OH                             4.00, d (6.0)                                                 11                10, 11, 12                   
  12                  32.1, CH      1.24, m                                                       11, 13, 29                                     9
  13a                 40.1, CH~2~   1.87, br. d (12.8)                                            12, 13b, 15, 29   11, 12, 14, 15, 27, 28, 29   13b
  13b                               1.51[a](#tfn1-marinedrugs-09-00098){ref-type="table-fn"}, m   12, 13a, 15, 29   11, 12, 14, 15, 27, 28, 29   13a, 15
  14                  132.8, C                                                                                                                   
  15                  132.7, CH     4.76, d (7.8)                                                 13, 16            12, 13, 16, 17, 27, 28       13b, 17, 29
  16                  29.4, CH      2.59, m                                                       15, 17, 27        14, 17, 27                   27, 28
  17a                 40.9, CH~2~   1.34, m                                                       16, 17b, 18       15, 16, 18, 19, 26, 27       17b
  17b                               1.05, ddd (13.5, 8.7, 5.0)                                    16, 17a, 18       15, 16, 18, 19, 26, 27       17a, 27
  18                  33.4, CH      1.75, m                                                       17, 19, 26        16, 17, 19, 20, 26           
  19                  77.4, CH      4.71, dt (10, 2.4)                                            18, 20            1, 17, 20, 21,26             21, 26
  20a                 27.9, CH~2~   1.52[a](#tfn1-marinedrugs-09-00098){ref-type="table-fn"}, m   19, 21                                         
  20b                               1.47[a](#tfn1-marinedrugs-09-00098){ref-type="table-fn"}, m   19, 21                                         
  21                  22.0, CH~2~   1.30[b](#tfn1-marinedrugs-09-00098){ref-type="table-fn"}, m   20                                             19
  22                  36.1, CH~2~   1.31[b](#tfn1-marinedrugs-09-00098){ref-type="table-fn"}, m   23                                             23, 23-OH
  23                  70.8, CH      3.28, m                                                       22, 23-OH, 24     21, 22, 25                   22, 25, 26
  23-OH                             4.25, d (5.2)                                                 23                22, 23, 24                   22, 26
  24a                 29.7, CH~2~   1.30[b](#tfn1-marinedrugs-09-00098){ref-type="table-fn"}, m   23, 25                                         25
  24b                               1.27[b](#tfn1-marinedrugs-09-00098){ref-type="table-fn"}, m   23, 25                                         25
  25                  10.1, CH~3~   0.82, t (7.4)                                                 24                23, 24                       23, 24
  26                  17.5, CH~3~   0.88, d (6.2)                                                 18                17, 18, 19                   19, 23, 23-OH
  27                  21.5, CH~3~   0.84, d (6.8)                                                 16                15, 16, 17                   16, 17b
  28                  17.0, CH~3~   1.53[a](#tfn1-marinedrugs-09-00098){ref-type="table-fn"}, s                     13, 14, 15                   16
  29                  17.7, CH~3~   0.58, d (6.7)                                                 12                11, 12, 13                   11, 15
  30                  11.1, CH~3~   0.86, d (5.9)                                                 10                9, 10, 11                    9, 11

signals are overlapping.

###### 

NMR spectroscopic data of the levantilides in acetone-*d*~6~ (500 MHz).

        levantilide A (1)   levantilide B (2)           
  ----- ------------------- ------------------- ------- ------
  1     166.9                                   166.9   
  2     122.0               5.83                121.9   5.83
  3     144.3               7.14                144.4   7.15
  4     131.9               6.36                131.9   6.36
  5     140.1               6.09                140.2   6.11
  6a    40.6                2.69                40.6    2.66
  6b                        2.47                        2.46
  7     69.3                4.11                69.4    4.10
  8a    33.8                1.73                33.9    1.72
  8b                        1.34                        1.34
  9     69.3                4.18                69.4    4.17
  10    42.2                1.86                42.3    1.86
  11    77.4                3.17                77.4    3.18
  12    33.2                1.41                33.3    1.41
  13a   41.4                2.00                41.4    1.99
  13b                       1.69                        1.69
  14    134.1                                   134.1   
  15    134.1               4.86                134.1   4.87
  16    30.7                2.70                30.7    2.69
  17a   41.9                1.47                41.9    1.43
  17b                       1.12                        1.11
  18    34.7                1.87                34.7    1.87
  19    78.8                4.83                78.6    4.81
  20a   28.9                1.61                28.3    1.57
  20b                       1.53                        1.50
  21a   23.3                1.42                21.3    1.62
  21b                                                   1.47
  22    37.6                1.42                42.1    2.45
  23    72.7                3.42                210.5   
  24a   31.1                1.43                36.0    2.42
  24b                       1.37                        
  25    10.4                0.90                8.0     0.96
  26    18.6                0.91                18.4    0.91
  27    22.0                0.86                21.8    0.87
  28    17.6                1.62                17.6    1.63
  29    18.5                0.70                18.4    0.71
  30    10.8                0.98                11.0    0.98

[^1]: Present address: Universität Bonn, Pharmazeutisches Institut, Pharmazeutische Chemie I, An der Immenburg 4, 53121 Bonn, Germany.
